CASE-BASED ROUNDTABLE

Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

Latest Articles

With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy

With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy

August 13, 2026

During a live event, Eric K. Singhi, MD, and participants discussed how CNS activity and cumulative toxicity, not guideline listing alone, are shaping frontline treatment selection in ROS1-positive advanced NSCLC.

Treatment Goals Guide First-Line Choices in Metastatic RCC

Treatment Goals Guide First-Line Choices in Metastatic RCC

August 12, 2026

Experts weigh response speed, survival and quality of life to choose first-line IO-TKI or dual immunotherapy for metastatic clear cell RCC.

Myeloma Physicians Consider Approaches to Subcutaneous Therapy

Myeloma Physicians Consider Approaches to Subcutaneous Therapy

August 11, 2026

During a live event, Sikander Ailawadhi, MD, and participants discussed how the route of CD38-antibody delivery, including a newly approved on-body injector, is shaping frontline regimen selection for transplant-ineligible multiple myeloma.

Oncologists Discuss CAR T Logistics and Bridging in Relapsed DLBCL

Oncologists Discuss CAR T Logistics and Bridging in Relapsed DLBCL

August 06, 2026

Explore how REMS removal streamlines CAR T access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

Experts Debate PD-1 Rechallenge After ICI Progression in RCC

Experts Debate PD-1 Rechallenge After ICI Progression in RCC

August 05, 2026

Experts weigh TiNivo-2 and CONTACT-03, urging caution on PD-1 rechallenge in RCC and guiding tivozanib vs cabozantinib choices.

How Desmoid Tumor Treatment Has Changed–And What's Next

How Desmoid Tumor Treatment Has Changed–And What's Next

August 05, 2026

Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how sequencing is the next major question.

In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade

In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade

August 04, 2026

During a live event, Millie Das, MD, and participants discussed why the case for adding a CTLA-4 inhibitor in PD-L1–low metastatic NSCLC does not hold uniformly once histology is taken into account.

Toxicity Considerations With Third-Line Treatment in KRAS Wild-Type mCRC

Toxicity Considerations With Third-Line Treatment in KRAS Wild-Type mCRC

During a live event, Midhun Malla, MD, and participants discussed toxicity considerations with third-line therapy selection for KRAS-mutant mCRC.

Navigating CAR T Decision-Making in R/R DLBCL

Navigating CAR T Decision-Making in R/R DLBCL

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

Changing ADC Choices for HR+/HER2– Breast Cancer

Changing ADC Choices for HR+/HER2– Breast Cancer

During a live event, Ruta Rao, MD, and participants discussed how the redefined HER2 spectrum is reshaping first antibody-drug conjugate selection in HR+/HER2– metastatic breast cancer.

Considering the Applications of On-Body Injector for Myeloma in Community Practice

Considering the Applications of On-Body Injector for Myeloma in Community Practice

Joseph Mikhael, MD, MEd, discusses how the on-body injection option for isatuximab can improve convenience for community oncology staff and patients.

Optimizing Second-Line Therapy in Metastatic ccRCC

Optimizing Second-Line Therapy in Metastatic ccRCC

Explore second-line options after ICI failure in metastatic ccRCC, featuring TiNivo-2 insights and tivozanib’s tolerability and PFS.

ROS1-Positive Lung Cancer: Key Takeaways from the Roundtable Discussions

ROS1-Positive Lung Cancer: Key Takeaways from the Roundtable Discussions

Experts weigh newer ROS1 inhibitors like taletrectinib, highlighting long responses, fewer CNS/GI side effects, and trial challenges in rare NSCLC.

Understanding the Sequencing Decisions in mCRPC After Progression on ADT/ARPI

Understanding the Sequencing Decisions in mCRPC After Progression on ADT/ARPI

During a live event, Matthew Rettig, MD, examined treatment options for a patient who had received prior doublet therapy for metastatic castration-resistant prostate cancer.

Multilineage Cytopenias, Not Neutropenia Alone, Are Driving Interest in Trilaciclib for ES-SCLC

Multilineage Cytopenias, Not Neutropenia Alone, Are Driving Interest in Trilaciclib for ES-SCLC

During an event, Julia Rotow, MD, and participants discussed how a real-world case of cascading anemia and thrombocytopenia shifted the group's thinking on multilineage prophylaxis for extensive-stage small cell lung cancer.

View a specific disease type